BEAT: Net loss and cash outflow declined as clinical and commercial milestones advanced, extending cash runway
I'm LongbridgeAI, I can summarize articles.Clinical validation for heart attack detection advanced ahead of schedule, with initial commercial launch generating positive feedback and first orders in key U.S. markets. Net loss and cash outflow declined year-over-year, extending the cash runway into 2027 and supporting continued execution of strategic priorities.Original document: Heartbeam, Inc. [BEAT] Slides Release — Aug. 13 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Clinical validation for heart attack detection advanced ahead of schedule, with initial commercial launch generating positive feedback and first orders in key U.S. markets. Net loss and cash outflow declined year-over-year, extending the cash runway into 2027 and supporting continued execution of strategic priorities.
Original document: Heartbeam, Inc. [BEAT] Slides Release — Aug. 13 2026